Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azelastine + fluticasone propionate
- Development stage
- Phase 4
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Azeflu is a fixed-dose combination nasal spray containing azelastine hydrochloride and fluticasone propionate. It is primarily indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis in patients who require both an antihistamine and a corticosteroid for symptom control. Azelastine is a second-generation H1-receptor antagonist that provides rapid relief of nasal symptoms by blocking histamine H1 receptors and inhibiting the release of inflammatory mediators. Fluticasone propionate is a synthetic corticosteroid that exerts potent anti-inflammatory effects by binding to glucocorticoid receptors, thereby reducing mucosal edema and inflammatory cell infiltration. This combination therapy is designed to provide superior efficacy compared to either component used alone by addressing both the immediate and late-phase allergic responses.
- Brand names
- Azeflu
- Other names
- Azeflu Nasal Spray
02
Targets
TAS2R (Taste receptor type 2 family)GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on azelastine + fluticasone propionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azelastine + fluticasone propionate.